Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study

Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown evidence of single-agent activity in glioblastoma (GBM), and in preclinical studies, we have demonstrated significant synergistic cytotoxicity between HDAC inhibitors and proteasome inhibitors in GBM cell lines. We therefore conducted a p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Friday, Bret B., Anderson, S. Keith, Buckner, Jan, Yu, Chunrong, Giannini, Caterina, Geoffroy, Francois, Schwerkoske, John, Mazurczak, Miroslaw, Gross, Howard, Pajon, Eduardo, Jaeckle, Kurt, Galanis, Evanthia
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2012
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3266383/
https://ncbi.nlm.nih.gov/pubmed/22090453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nor198
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados